Fig. 3: VARS activity is increased in melanoma resistant to targeted therapy.
From: Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma
a, Expression of aaRSs in M395 RES cultures (proteomics; n = 3, two-tailed unpaired t-test). b, VARS expression in SENS and RES cultures as confirmed by western blot (n = 2). c, Val-MAC tRNA and Ile-RAT tRNA aminoacylation analysis of M395 SENS and RES cells (mean ± s.e.m. of n = 2 independent replicates). d, VARS expression in SENS and RES to dual MAPK-targeted therapy (n = 2). e, Survival analysis of patients with SKCM with high or low expression of VARS. TPM, transcripts per million. HR, hazards ratio. f, Evaluation of the skin of patients with cutaneous melanoma overall survival (data from TCGA) related to the expression of all the tRNA synthetase. VARS expression is associated with the poorest prognosis in patients with SKCM. The P values were obtained from GEPIA2. g, VARS immunostaining in patients with normal skin (n = 12) and primary (n = 12) or metastatic (n = 21) melanoma biopsies. The representative images and quantifications are shown, and a chi-squared test was performed.
